B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

0.00

B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ: TSHA) with a Buy and raises the price target from $9 to $10.